TAG:
clfs
Did Some Lab Execs ‘Get What They Wished For?’
By R. Lewis Dark | From the Volume XXII No. 14 – October 5, 2015 Issue
BY NOW, MOST OF YOU HAVE LEARNED that, just 12 days ago, CMS issued the proposed rule that details how it will handle the private market price reporting mandate of the Protecting Access to Medicare Act of 2014 (PAMA). Almost immediately, critics spoke out about the obvious inequities that will re…
Beware Ides of March! Lawmakers Are in Session
By Joseph Burns | From the Volume XXII No. 4 – March 9, 2015 Issue
CEO SUMMARY: Few pathologists and lab administrators know that, when the Protecting Access to Medicare Act of 2014 (PAMA) became law last April 1, language in the bill was scored to reduce Part B clinical laboratory test fees by $2.5 billion over 10 years. Congress used those lab…
PAMA’s New Rules Affect Lab Test Pricing, Coverage
By Joseph Burns | From the Volume XXI No. 8 – June 9, 2014 Issue
CEO SUMMARY: For several reasons, the “Protecting Access to Medicare Act” (PAMA) has the potential to be the most disruptive federal legislation directed at the clinical lab industry since the enactment of CLIA 1988. Following passage of the law, some lab industry groups have taken di…
Speakers in New Orleans Offer Important Insights
By Robert Michel | From the Volume XXI No. 7 – May 19, 2014 Issue
CEO SUMMARY: In coming years, there will be multiple challenges and opportunities for the nation’s clinical laboratories and pathology groups. That was one common theme heard from the 90 speakers and panelists at the 19th annual Executive War College on Laboratory and Pathology Manageme…
New Pricing Formula for Advanced Diagnostic Tests
By R. Lewis Dark | From the Volume XXI NO. 6 – April 28, 2014 Issue
CEO SUMMARY: One section of the federal H.R. 4302: Protecting Access to Medicare Act of 2014 is getting positive reviews from many lab experts. The law defines advanced diagnostic tests (ADTs) and directs CMS to assign a temporary HCPCS code and use list prices to pay labs for such tests …
New Federal Law Changes How CMS Sets Lab Prices
By Robert Michel | From the Volume XXI No. 5 – April 7, 2014 Issue
CEO SUMMARY: CMS wanted more power to cut the prices it pays for clinical lab testing. A significant part of the lab industry wanted more transparency and consistency in how CMS established coverage guidelines and prices for new lab tests. Congress appears to have attempted to craft a law…
Medicare OPPS Rule Has Pitfalls for Labs
By Joseph Burns | From the Volume XXI No. 2 – February 3, 2014 Issue
CEO SUMMARY: On January 1, the new Medicare rule for requiring bundled or packaged reimbursement for certain services covered by the hospital Outpatient Prospective Payment System (OPPS) became effective. Just four days earlier (on December 27), Medicare officials issued instructions on h…
Tennessee BCBS Cuts Lab Fees to 52% of Medicare
By Joseph Burns | From the Volume XX, No. 17 – December 23, 2013 Issue
CEO SUMMARY: Blue Cross Blue Shield of Tennessee has notified physicians that, starting January 1, it will reduce what it pays for lab testing to 52% of Medicare fees. Officials with the state medical association have been unable to get definitive answers to questions about what tests wou…
Study Reveals Medicare Already Pays Low Rates
By Joseph Burns | From the Volume XX, No. 17 – December 23, 2013 Issue
CEO SUMMARY: Researchers studied a database containing laboratory test prices paid in 2012 on behalf of 56 million Americans covered by private health plans and determined that, for most tests, and in most regions, Medicare already pays less than private health insurers for clinical labor…
ACLA, CAP Comment on Final 2014 Medicare Rules
By Joseph Burns | From the Volume XX, No. 16 – December 2, 2013 Issue
CEO SUMMARY: On November 27, as the nation prepared for the Thanksgiving holiday, the federal Centers for Medicare & Medicaid Services (CMS) announced the long-awaited final rules for 2014. Early analysis of the 1,300 pages of rules CMS released indicates that the agency moderated one…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized